ATE488240T1 - Mittel zur behanldung von krankheiten zur aufbringung auf das auge - Google Patents

Mittel zur behanldung von krankheiten zur aufbringung auf das auge

Info

Publication number
ATE488240T1
ATE488240T1 AT04727990T AT04727990T ATE488240T1 AT E488240 T1 ATE488240 T1 AT E488240T1 AT 04727990 T AT04727990 T AT 04727990T AT 04727990 T AT04727990 T AT 04727990T AT E488240 T1 ATE488240 T1 AT E488240T1
Authority
AT
Austria
Prior art keywords
estrogen
eye
agents
application
treating diseases
Prior art date
Application number
AT04727990T
Other languages
English (en)
Inventor
Shinseiro Okamoto
Original Assignee
Advanced Medicine Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2004/004709 external-priority patent/WO2004093882A1/ja
Application filed by Advanced Medicine Res Inst filed Critical Advanced Medicine Res Inst
Application granted granted Critical
Publication of ATE488240T1 publication Critical patent/ATE488240T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04727990T 2003-04-18 2004-04-16 Mittel zur behanldung von krankheiten zur aufbringung auf das auge ATE488240T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2003114969 2003-04-18
JP2003132910 2003-05-12
JP2003329165 2003-09-19
JP2003354135 2003-10-14
PCT/JP2004/004709 WO2004093882A1 (ja) 2003-04-18 2004-03-31 眼に適用する疾患治療剤
PCT/JP2004/005479 WO2004091630A1 (ja) 2003-04-18 2004-04-16 眼に適用する疾患治療剤

Publications (1)

Publication Number Publication Date
ATE488240T1 true ATE488240T1 (de) 2010-12-15

Family

ID=33304160

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04727990T ATE488240T1 (de) 2003-04-18 2004-04-16 Mittel zur behanldung von krankheiten zur aufbringung auf das auge

Country Status (7)

Country Link
EP (6) EP1621199B8 (de)
JP (2) JP4564920B2 (de)
AT (1) ATE488240T1 (de)
AU (1) AU2004229291A1 (de)
CA (1) CA2527175A1 (de)
DE (1) DE602004030103D1 (de)
WO (1) WO2004091630A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE488240T1 (de) * 2003-04-18 2010-12-15 Advanced Medicine Res Inst Mittel zur behanldung von krankheiten zur aufbringung auf das auge
US8030350B2 (en) * 2005-02-24 2011-10-04 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
WO2006127987A2 (en) * 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
EP2442812A1 (de) 2009-06-19 2012-04-25 Altos Vision Limited Retard- und mikrodosis-formulierungen für die topische anwendung von östrogen und östrogenanaloga oder anderen östrogenrezeptormodulatoren bei der behandlung von trockenem auge sowie zubereitungs- und anwendungsverfahren
EP3539542B1 (de) 2009-06-22 2023-04-19 Diffusion Pharmaceuticals LLC Verteilungsverbesserte verbindungen und ihre verwendung mit einem thrombolyticum
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
CN103124498A (zh) 2010-06-02 2013-05-29 扩散药品有限公司 双极性反式类胡萝卜素的口服制剂
JP2016503797A (ja) 2012-12-20 2016-02-08 アルデイラ セラピューティクス， インコーポレイテッド ペリ−カルビノール
CA3195807A1 (en) 2013-01-23 2014-07-31 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
CN105228989A (zh) 2013-01-25 2016-01-06 奥尔德拉医疗公司 黄斑变性治疗中的新颖捕获剂
MX2018002155A (es) 2015-08-21 2018-06-08 Aldeyra Therapeutics Inc Compuestos deuterados y usos de los mismos.
CN109069530A (zh) 2016-02-28 2018-12-21 奥尔德拉医疗公司 用环糊精治疗过敏性眼部病状
JP7032320B2 (ja) 2016-03-24 2022-03-08 ディフュージョン・ファーマシューティカルズ・エルエルシー 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用
WO2017196881A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
AU2018234919A1 (en) 2017-03-16 2019-09-19 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP6923917B2 (ja) * 2017-09-21 2021-08-25 国立大学法人福井大学 白内障の予防剤および治療剤、ならびに、これらを製造するためのｈｉｆ経路阻害剤の使用
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN113056353B (zh) 2018-09-25 2022-11-01 奥尔德拉医疗公司 用于治疗干眼病的调配物
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用
WO2022255282A1 (ja) * 2021-05-31 2022-12-08 国立大学法人大阪大学 動体視力向上用組成物
CN115105512A (zh) * 2022-08-29 2022-09-27 中山大学中山眼科中心 脱氢表雄酮在制备预防、治疗眼部近视的药物中的用途及其剂型和制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
SE8305864D0 (sv) * 1983-10-25 1983-10-25 L E Medical Ogondroppar
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
DE69122764T2 (de) * 1990-08-31 1997-03-20 Teruo Nishida Arznei gegen hornhautbeschädigungen
ES2139602T3 (es) * 1991-06-18 2000-02-16 Theramex Composiciones oculares que contienen esteroides y su utilizacion para el tratamiento del glaucoma.
JP2531558B2 (ja) * 1991-08-17 1996-09-04 ルブキン、バージニア ドライアイ症処置用の性ステロイド膏薬、同薬の調製法および適用法
DK0614463T3 (da) * 1991-11-22 2003-03-31 Alcon Lab Inc Angiostatiske steroider
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
AU672862B2 (en) * 1992-12-02 1996-10-17 Insite Vision Incorporated Cyclodextrin and polymer based drug delivery system
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
US6142989A (en) * 1993-05-03 2000-11-07 O'donnell, Jr.; Francis E. Apparatus and method for customized laser correction of refractive error
US5556395A (en) * 1993-05-07 1996-09-17 Visx Incorporated Method and system for laser treatment of refractive error using an offset image of a rotatable mask
NZ270077A (en) * 1993-12-14 1996-04-26 Lilly Co Eli Aqueous complexes of benzothiophenes and cyclodextrins
US5521168A (en) 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
WO1997003677A1 (en) * 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
WO1998002155A1 (en) * 1996-07-12 1998-01-22 Novo Nordisk A/S 2-phenyl-3-azoylbenzothiophene for lowering intraocular pressure
EP1806131A3 (de) * 1996-07-22 2007-08-01 Renovo Limited Verwendung von Sex-Steroid-Funktionsmodulatoren zur Behandlung von Wunden und fibrotischen Erkrankungen
AUPO427196A0 (en) * 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
JP3764047B2 (ja) * 1998-03-12 2006-04-05 ジェネンテック・インコーポレーテッド 網膜ニューロン死の防止及び眼病の治療方法
EP1142585A4 (de) * 1999-01-12 2005-08-03 Santen Pharmaceutical Co Ltd Arznei gegen krankheiten der cornea
US20010041745A1 (en) * 1999-04-08 2001-11-15 Bryant Henry Uhlman Methods for increasing levels of acetylcholine
CN1220491C (zh) * 1999-06-11 2005-09-28 沃特森药物公司 非口服雄激素类固醇用于制备改善性激素结合球蛋白水平升高的药物
AU1735001A (en) * 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
EP1177787A3 (de) * 2000-07-28 2003-09-10 Pfizer Products Inc. Verwendung von einem Östrogen Agonist/Antagonist zur Behandlung von Katarakt
US6605640B2 (en) * 2001-01-31 2003-08-12 Gerard M. Nolan Method of treating certain eye diseases
WO2002040032A2 (en) 2000-11-17 2002-05-23 Washington University Cytoprotective estrogen derivatives
JP2004519511A (ja) * 2001-02-13 2004-07-02 ドクトル ゲルハルト マン ケム−ファルム． ファブリック ゲゼルシャフト ミット ベシュレンクテル ハフツンク 視神経組織変性疾患治療用のｇａｂａ受容体モジュレータ
TWI320712B (en) * 2001-09-05 2010-02-21 Alcon Inc The use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma
ATE488240T1 (de) * 2003-04-18 2010-12-15 Advanced Medicine Res Inst Mittel zur behanldung von krankheiten zur aufbringung auf das auge

Also Published As

Publication number Publication date
EP2289488A2 (de) 2011-03-02
AU2004229291A1 (en) 2004-10-28
EP1621199B8 (de) 2011-01-19
DE602004030103D1 (de) 2010-12-30
EP2305308A1 (de) 2011-04-06
EP2292239A2 (de) 2011-03-09
EP2301549A1 (de) 2011-03-30
EP1621199A4 (de) 2006-09-27
JP4564920B2 (ja) 2010-10-20
EP2311465A1 (de) 2011-04-20
CA2527175A1 (en) 2004-10-28
EP1621199B1 (de) 2010-11-17
JP2010184927A (ja) 2010-08-26
JPWO2004091630A1 (ja) 2006-08-17
EP2289488A3 (de) 2011-03-30
EP1621199A1 (de) 2006-02-01
WO2004091630A1 (ja) 2004-10-28
EP2292239A3 (de) 2011-03-30
WO2004091630A8 (ja) 2005-11-24

Similar Documents

Publication Publication Date Title
ATE488240T1 (de) Mittel zur behanldung von krankheiten zur aufbringung auf das auge
ECSP20025070A (es) Proteínas trispecificas y métodos de uso
PT1100516E (pt) Extratos de matricaria (tanacetum parthenium) contra doencas inflamatorias
ATE486860T1 (de) Phenothiazin-derivat zur wundheilung
CR10169A (es) "uso de derivados de sulfamida heterociclica benzo-fusionada para disminuir lipidos y disminuir niveles de glucosa en la sangre"
BRPI0417932A (pt) lipólise medicamentosa de acúmulo de gordura
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
EA200970154A1 (ru) Косметические или дерматологические препараты, содержащие n-ацетилцистеин
ATE550015T1 (de) Verfahren und zusammensetzung zur behandlung von rhinitis
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
WO2006039231A3 (en) Topical formulations for the treatment of depression with s adenosyl methionine
DE60001555D1 (de) Wässrige lösung zum konservieren von gewebe und organen
ATE326947T1 (de) Thixotropes nasenspray
AR030345A1 (es) Metodo de tratamiento de desordenes relacionados con angiogenesis
AR043252A1 (es) Formulaciones de glucocorticoesteroides para tratar angiogenia ocular patologica
AR048693A1 (es) Composicion cosmetica de tipo emulsion de agua-en-aceite que contiene una sal activa desodorante y un emulsor derivado de poliolefina que lleva al menos una parte polar
MX2022009081A (es) Absorcion celular.
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
EA200700983A1 (ru) Применение андрогенов для снижения вероятности приобретения или лечения старения кожи
AR015761A1 (es) Un derivado del acido 2-metilpropionico,una composicion farmaceutica que lo incluye, uso de un derivado del acido 2-metilpropionico y un procedimiento parala fabricacion de una composicion farmaceutica para la prevencion o el tratamiento de enfermedades
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
ES2170726B1 (es) Procedimiento para la obtencion de un extracto aislado de la planta cyclamen europaeum l. y su utilizacion como agente terapeutico.
PE122099A1 (es) Budesonida sola o en combinacion con acido ursodesoxicolico en la terapia de enfermedades colestasicas del higado
BR0202358A (pt) Gel para tratamento de estrias
UA6873U (en) Method for treating psoriasis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties